Alkermes Enters Material Definitive Agreement

TL;DR

Alkermes just signed a big deal, expect financial obligations.

AI Summary

Alkermes plc. announced on November 18, 2025, that it has entered into a material definitive agreement. This agreement also creates a direct financial obligation for the company. Further details regarding the nature of the agreement and the financial obligations are expected to be disclosed.

Why It Matters

This filing indicates a significant new contract or financial commitment for Alkermes, which could impact its future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements and financial obligations can introduce new risks related to performance, integration, or market reception.

Key Players & Entities

• Alkermes plc. (company) — Registrant
• November 18, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.01 — e on which registered Ordinary shares, $0.01 par value ALKS Nasdaq Global Select
• $18.50 — rdinary share capital of Avadel for (i) $18.50 per ordinary share, nominal value $0.01
• $1.50 — a potential additional cash payment of $1.50 per Avadel Share, contingent upon achie
• $21.00 — nded Transaction Agreement increased to $21.00 per Avadel Share and with the terms of
• $1,512,562,923.28 — an aggregate principal amount of up to $1,512,562,923.28 that is available to finance the paymen

Filing Documents

• d858713d8k.htm (8-K) — 45KB
• d858713dex21.htm (EX-2.1) — 22KB
• d858713dex101.htm (EX-10.1) — 896KB
• d858713dex991.htm (EX-99.1) — 132KB
• g858713g1119012551128.jpg (GRAPHIC) — 3KB
• 0001193125-25-286909.txt ( ) — 1488KB
• alks-20251118.xsd (EX-101.SCH) — 3KB
• alks-20251118_lab.xml (EX-101.LAB) — 18KB
• alks-20251118_pre.xml (EX-101.PRE) — 11KB
• d858713d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1 Amendment No. 1 to the Transaction Agreement, dated as of November 18, 2025, by and between Alkermes plc and Avadel Pharmaceuticals plc 10.1 Amended and Restated Bridge Term Loan Credit Agreement, dated as of November 18, 2025 by and among Alkermes plc, Alkermes, Inc. and JPMorgan Chase Bank, N.A.* 99.1 Revised offer announcement, dated as of November 19, 2025 104 Cover page interactive data file (embedded within the Inline XBRL document) * Certain schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. Responsibility Statement Required by the Takeover Rules The members of Alkermes' board of directors accept responsibility for the information contained in this Current Report on Form 8-K other than that relating to Avadel, its Subsidiaries and Avadel's board of directors and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the members of Alkermes' board of directors (who have taken all reasonable care to ensure that such is the case), the information contained in this Current Report on Form 8-K for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. No Offer or Solicitation This Current Report on Form 8-K is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of a